Biohaven BHVN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Biohaven (BHVN) Business Model and Operations Summary
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Key Insights
Biohaven (BHVN) Core Market Data and Business Metrics
Latest Closing Price
$22.6Market Cap
$2.33 BillionPrice-Earnings Ratio
-6.65Total Outstanding Shares
102.07 Million SharesTotal Employees
256Dividend
No dividendIPO Date
September 23, 2022SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
215 Church Street, New Haven, CT, 06510
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-141.28 Million |
| Net Cash Flow From Investing Activities, Continuing | $-93.40 Million |
| Exchange Gains/Losses | $0 |
| Net Cash Flow, Continuing | $-154.30 Million |
| Net Cash Flow From Financing Activities, Continuing | $80.38 Million |
| Net Cash Flow From Operating Activities | $-141.28 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Nonoperating Income/Loss | $17.80 Million |
| Income/Loss From Continuing Operations After Tax | $-160.30 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-160.30 Million |
| Research and Development | $157.61 Million |
| Diluted Average Shares | $94.37 Million |
| Income/Loss From Continuing Operations Before Tax | $-160.36 Million |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-160.09 Million |
| Comprehensive Income/Loss | $-160.09 Million |
| Other Comprehensive Income/Loss | $218,000 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Assets | $70.02 Million |
| Liabilities And Equity | $510.52 Million |
| Intangible Assets | $18.40 Million |
| Wages | $15.88 Million |
| Noncurrent Liabilities | $42.22 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||